However, they do mention that some TLR4 antagonists including Eritoran and TAK242 (both proposed here) were used successfully in the treatment of inflammation associated with cancer, rheumatoid arthritis, and other inflammatory diseases ([151] and references therein). The gene discussed is TLR4; the disease is cancer.